Current Status of Biomarkers for Prostate Cancer
AbstractProstate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa. It is now evident that the PSA test produces unacceptably high rates of false positive results and is not prognostic. Here we review the current status of molecular biomarkers that promise to be prognostic and that might inform individual patient management. It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunology, and cancer-associated microparticles. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Velonas, V.M.; Woo, H.H.; Remedios, C.G.; Assinder, S.J. Current Status of Biomarkers for Prostate Cancer. Int. J. Mol. Sci. 2013, 14, 11034-11060.
Velonas VM, Woo HH, Remedios CG, Assinder SJ. Current Status of Biomarkers for Prostate Cancer. International Journal of Molecular Sciences. 2013; 14(6):11034-11060.Chicago/Turabian Style
Velonas, Vicki M.; Woo, Henry H.; Remedios, Cristobal G.; Assinder, Stephen J. 2013. "Current Status of Biomarkers for Prostate Cancer." Int. J. Mol. Sci. 14, no. 6: 11034-11060.